Arcellx Inc ACLX.O:
GILEAD SCIENCES TO ACQUIRE ARCELLX TO MAXIMIZE LONG-TERM POTENTIAL OF ANITO-CEL
GILEAD - TO BUY ARCELLX FOR $115 PER SHARE IN CASH
GILEAD - DEAL REPRESENTS IMPLIED EQUITY VALUE OF $7.8 BILLION
GILEAD - DEAL EXPECTED TO BE ACCRETIVE TO EPS IN 2028 AND THEREAFTER
Source text: ID:nBw9F864Ha
Further company coverage: ACLX.O
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.